955 related articles for article (PubMed ID: 28177518)
1. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
3. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
[TBL] [Abstract][Full Text] [Related]
4. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and clinicopathological characteristics of ALK fusion subtypes in lung adenocarcinomas from Chinese populations.
Zheng D; Wang R; Zhang Y; Pan Y; Cheng X; Cheng C; Zheng S; Li H; Gong R; Li Y; Shen X; Sun Y; Chen H
J Cancer Res Clin Oncol; 2016 Apr; 142(4):833-43. PubMed ID: 26646246
[TBL] [Abstract][Full Text] [Related]
6. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
7. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
8. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
9. Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.
Paik PK; Johnson ML; D'Angelo SP; Sima CS; Ang D; Dogan S; Miller VA; Ladanyi M; Kris MG; Riely GJ
Cancer; 2012 Dec; 118(23):5840-7. PubMed ID: 22605530
[TBL] [Abstract][Full Text] [Related]
10. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
12. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
14. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
[No Abstract] [Full Text] [Related]
15. Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Cagle PT; Raparia K; Portier BP
Adv Exp Med Biol; 2016; 890():25-36. PubMed ID: 26703797
[TBL] [Abstract][Full Text] [Related]
16. Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.
Zhang S; Yan B; Zheng J; Zhao J; Zhou J
Oncotarget; 2016 Sep; 7(39):63758-63766. PubMed ID: 27563816
[TBL] [Abstract][Full Text] [Related]
17. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
18. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
20. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]